147 related articles for article (PubMed ID: 38575671)
61. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.
Yin S; Gambe RG; Sun J; Martinez AZ; Cartun ZJ; Regis FFD; Wan Y; Fan J; Brooks AN; Herman SEM; Ten Hacken E; Taylor-Weiner A; Rassenti LZ; Ghia EM; Kipps TJ; Obeng EA; Cibulskis CL; Neuberg D; Campagna DR; Fleming MD; Ebert BL; Wiestner A; Leshchiner I; DeCaprio JA; Getz G; Reed R; Carrasco RD; Wu CJ; Wang L
Cancer Cell; 2019 Feb; 35(2):283-296.e5. PubMed ID: 30712845
[TBL] [Abstract][Full Text] [Related]
62. Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
Machnicki MM; Górniak P; Pępek M; Szymczyk A; Iskierka-Jażdżewska E; Steckiewicz P; Bluszcz A; Rydzanicz M; Hus M; Płoski R; Makuch-Łasica H; Nowak G; Juszczyński P; Jamroziak K; Stokłosa T; Puła B
Eur J Haematol; 2021 Mar; 106(3):320-326. PubMed ID: 33190294
[TBL] [Abstract][Full Text] [Related]
63. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
64. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
[TBL] [Abstract][Full Text] [Related]
65. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.
Furman RR; Asgary Z; Mascarenhas JO; Liou HC; Schattner EJ
J Immunol; 2000 Feb; 164(4):2200-6. PubMed ID: 10657675
[TBL] [Abstract][Full Text] [Related]
66. Signalling to drug resistance in CLL.
Hertlein E; Byrd JC
Best Pract Res Clin Haematol; 2010 Mar; 23(1):121-31. PubMed ID: 20620976
[TBL] [Abstract][Full Text] [Related]
67. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia.
Zhang W; Kater AP; Widhopf GF; Chuang HY; Enzler T; James DF; Poustovoitov M; Tseng PH; Janz S; Hoh C; Herschman H; Karin M; Kipps TJ
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18956-60. PubMed ID: 20956327
[TBL] [Abstract][Full Text] [Related]
68. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
[TBL] [Abstract][Full Text] [Related]
69. CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway.
Browning RL; Mo X; Muthusamy N; Byrd JC
Oncotarget; 2015 Jun; 6(18):15931-9. PubMed ID: 26158860
[TBL] [Abstract][Full Text] [Related]
70. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents.
Paiva C; Godbersen JC; Berger A; Brown JR; Danilov AV
Cell Death Dis; 2015 Jul; 6(7):e1807. PubMed ID: 26158513
[TBL] [Abstract][Full Text] [Related]
71. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.
Hertlein E; Wagner AJ; Jones J; Lin TS; Maddocks KJ; Towns WH; Goettl VM; Zhang X; Jarjoura D; Raymond CA; West DA; Croce CM; Byrd JC; Johnson AJ
Blood; 2010 Jul; 116(1):45-53. PubMed ID: 20351313
[TBL] [Abstract][Full Text] [Related]
72. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
[TBL] [Abstract][Full Text] [Related]
73. The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Xargay-Torrent S; López-Guerra M; Rosich L; Montraveta A; Roldán J; Rodríguez V; Villamor N; Aymerich M; Lagisetti C; Webb TR; López-Otín C; Campo E; Colomer D
Oncotarget; 2015 Sep; 6(26):22734-49. PubMed ID: 26068951
[TBL] [Abstract][Full Text] [Related]
74. Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-kappaB activation.
Hammadi A; Billard C; Faussat AM; Kolb JP
Nitric Oxide; 2008 Sep; 19(2):138-45. PubMed ID: 18474259
[TBL] [Abstract][Full Text] [Related]
75. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.
Cuní S; Pérez-Aciego P; Pérez-Chacón G; Vargas JA; Sánchez A; Martín-Saavedra FM; Ballester S; García-Marco J; Jordá J; Durántez A
Leukemia; 2004 Aug; 18(8):1391-400. PubMed ID: 15175625
[TBL] [Abstract][Full Text] [Related]
76. Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.
Saleh LM; Wang W; Herman SE; Saba NS; Anastas V; Barber E; Corrigan-Cummins M; Farooqui M; Sun C; Sarasua SM; Zhao Z; Abousamra NK; Elbaz O; Abdelghaffar HA; Wiestner A; Calvo KR
Leukemia; 2017 Feb; 31(2):340-349. PubMed ID: 27431016
[TBL] [Abstract][Full Text] [Related]
77. Reductions in I kappa B epsilon and changes in NF-kappa B activity during B lymphocyte differentiation.
Doerre S; Mesires KP; Daley KM; McCarty T; Knoetig S; Corley RB
J Immunol; 2005 Jan; 174(2):983-91. PubMed ID: 15634922
[TBL] [Abstract][Full Text] [Related]
78. AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
Cosimo E; Tarafdar A; Moles MW; Holroyd AK; Malik N; Catherwood MA; Hay J; Dunn KM; Macdonald AM; Guichard SM; O'Rourke D; Leach MT; Sansom OJ; Cosulich SC; McCaig AM; Michie AM
Clin Cancer Res; 2019 Mar; 25(5):1574-1587. PubMed ID: 30559170
[TBL] [Abstract][Full Text] [Related]
79. AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-kappaB survival pathway.
Escobar-Díaz E; López-Martín EM; Hernández del Cerro M; Puig-Kroger A; Soto-Cerrato V; Montaner B; Giralt E; García-Marco JA; Pérez-Tomás R; Garcia-Pardo A
Leukemia; 2005 Apr; 19(4):572-9. PubMed ID: 15744353
[TBL] [Abstract][Full Text] [Related]
80. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
